Estimated Time
1.00 hour
Release Date
May 31, 2023
Expiration Date
May 30, 2024
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table TalkTM episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM). This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations. In this exclusive, Special Edition Med Table TalkTM episode, our academic and community oncology experts will explore the following key points:
- Emerging evidence, rationale, and clinical implications for the use of CAR T-cell therapy in the early versus late stages of relapse, with insights into how disease biology and overall outcomes differ among these patient populations(eg, high-risk, early relapse, TCE, etc).
- Best practices for fostering interprofessional collaboration between cellular therapist facilities and community oncology practice settings, focusing on strategies to enhance teamwork as a means to enhance patient care and optimize the use of CAR T-cell therapy.
- Approaches to ensure timely referral and initiation of treatment through clinical trials, specifically focusing on reaching patients from underrepresented communities, facilitating access and representation to CAR T-cell therapies in clinically appropriate patients.
Speakers
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY
Dr. Saad Zafar Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He then joined the Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences in Little Rock, AR in 2010 as the Director of Developmental Therapeutics and Assistant Professor of Medicine. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies where he built an internationally renowned myeloma program. He now serves as the Chief of Myeloma Service at MSKCC.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS CDP Achievement Award. Dr. Usmani has authored/co-authored more than 230 peer-reviewed research manuscripts and over 300 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani has research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.
Krina K. Patel, MD, MSc
Associate Professor
Lymphoma/Myeloma Department
The University of Texas MD Anderson Cancer Center Houston, TX
Dr. Krina K. Patel is an associate professor in the Department of Lymphoma and Myeloma, Division of Cancer Medicine, and was previously in the Department of Stem Cell Transplantation, at the University of Texas MD Anderson Cancer Center (UT MDACC) in Houston Texas. She earned her bachelor’s degree at the University of Pennsylvania, medical degree from the University of Texas Southwestern Medical Center, Dallas and completed a fellowship in hematology-oncology at UT MDACC where she served as Chief fellow for 2 years and completed her Master of Science in the lab of Laurence Cooper MD PHD evaluating the combination of NY-ESO-1 T-APC vaccine with TCR in Multiple Myeloma cell line and mouse models. She currently serves as the Center Medical Director and Service Line Leader for her department.
Dr. Patel’s research focus is on improving therapy and outcomes for patients with MM and other plasma cell dyscrasias. Her specific research interests include improving survival and quality of life for patients with MM, POEMS, and plasmablastic lymphoma, using cellular therapy such as chimeric antigen receptor T cells with or without transplant and combining immunotherapy in the induction, transplant, maintenance, and salvage settings. She has acted as principal investigator on several MM clinical trials with a focus on immunotherapies such as novel CAR T, monoclonal antibodies, cytokines, and vaccine studies. She is also currently co-PI for a translational study evaluating ctDNA and scRNAseq data for patients undergoing standard of care CAR T studies. Outside of her clinical and translational interests, Dr. Patel is dedicated to improving outcomes and access to these novel therapies for vulnerable patient populations such as minority patient groups and those with high risk disease.
Dr. Patel is a member of ASH, ASCO, ASGCT, AACR, and ASTCT. Her research has been published in numerous peer-reviewed journals.
Melody Smith, MD, MS
Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA
Dr. Melody Smith received her MD with Distinction in Research from the University of Texas Southwestern Medical School in Dallas. She also completed an internship and residency in Internal Medicine at the University Texas Southwestern. She subsequently moved to Memorial
Sloan Kettering Cancer Center (MSK) to complete her fellowship in Hematology & Medical Oncology. She joined the faculty at MSK in 2015 as an Instructor of Medicine on the Adult Bone Marrow Transplant Service, and she was promoted to Assistant Member Level 1 in 2017.
During her time as junior faculty at MSK, she obtained a Master of Science from Weill Cornell Graduate School of Medical Sciences in Clinical & Translational Investigation. She performed her post-doctoral research in the lab of Marcel van den Brink, MD, PhD and she was co-mentored by Michel Sadelain, MD, PhD.
In September 2021, she joined the faculty at Stanford University as an Assistant Professor in the Division of Blood and Marrow Transplantation and Cellular Therapy in the Department of Medicine to establish her independent lab. As a physician-scientist, her independent research in
the lab focuses on strategies to develop cellular immunotherapy from allogeneic as opposed to autologous sources. She also investigates the regulatory mechanisms for the impact of the intestinal microbiome on chimeric antigen receptor (CAR) T cell outcomes.
Sanjay Sharma, MD
St. Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA
Dr. Sanjay Sharma is a highly accomplished hematologist oncologist with 18 years of experience at St Jude Heritage Medical Group, Providence Health System, Fullerton, CA. He has held various leadership roles during his tenure, including serving as Director of the Crosson Cancer Institute and has peer-reviewed publications. He graduated from medical school at Virginia Commonwealth Univ, internal medicine residency at Washington University in St Louis and fellowship at Mt Sinai Hospital NYC where he was chief fellow. In addition to his work in the medical field, Dr. Sharma is founder of Ishash Inc, a medical education company, founder of Physician Real Estate Nation, and general principal in multifamily syndications. Dr. Sharma is known for his dedication to improving the lives of his patients and for his commitment to advancing medical education and research.
Accreditation and Disclosure Information
Target Audience
This activity is intended for hematologic oncology clinicians, nurses, pharmacists, pathologists, and other members of the multidisciplinary and interprofessional care team who diagnose and/or treat individuals with multiple myeloma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Evaluate the rationale and significance of CAR T-cell therapies in addressing an unmet need for response durability in early versus late relapsed/refractory multiple myeloma.
- Explain the clinical implications for current and emerging evidence for the earlier use of CAR T-cell therapy in MM, particularly among those experiencing early relapse after first-line therapy or after triple-class exposure.
- Design practical approaches for the optimal use and timing of CAR T-cell therapies in practice, with considerations to promoting clinical trial enrollment and access to underrepresented communities.
Program Agenda
Part 1: Current Paradigms and Unmet Needs in the Management of Multiple Myeloma
- Introduction
- Appropriate risk stratification and prognosis as a means to guide MM treatment selection
- Current national guideline recommendations and FDA-approved indications for the treatment of early vs. late relapsed/refractory MM
- Rationale for earlier use of CAR T-cell therapies
- Community Oncologist Perspective and Panel Discussion
Part 2: Emerging Evidence for CAR T-cell Therapy Use Earlier in the MM Treatment Paradigm
- Clinical data for CAR T-cell therapies in earlier stage disease, TCE and/or early frontline relapse
- Clinical implications of data and emerging evidence
- Community Oncologist Perspective on Data
- Early identification in determining the optimal candidates for CAR T-cell therapy
- Key Points
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and no contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-045-H01-P
Type of Activity: Knowledge
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 30, 2024. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported through an educational grant from Bristol Myers Squibb.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY
Saad Z. Usmani, MD, MBA, FACP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
Research Grant: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Planner/Presenter
Melody Smith, MD, MS
Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA
Melody Smith, MD, MS, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Bristol Myers Squibb
Planner/Presenter
Krina K. Patel, MD, MSc
Associate Professor
Lymphoma/Myeloma Department
The University of Texas MD Anderson Cancer Center
Houston, TX
Krina K. Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Curio Bioscience, Janssen, Karyopharm, Legend Biotech, Merck, Oncopeptides, Pfizer, Precision Biosciences
Research Grant: AbbVie, Allogene, Arcellx, Bristol Myers Squibb, Celgene, Cellectis, Janssen, Nektar, Poseida, Precision Biosciences, Takeda
Presenter
Sanjay Sharma, MD
St Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA
Sanjay Sharma, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau: AstraZeneca, Bristol Myers Squibb, EMD Serono, Guardant Health, Merck
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.